Long QT2 mutation on the Kv11.1 ion channel inhibits current activity by ablating a protein kinase Cα consensus site

Alexander J Donovan1, Katherine Lansu, Jason G Williams

  • 1Departments of Molecular Pharmacology and Therapeutics, Loyola University, Chicago, Illinois, USA.

Insights

Mutations in the Kv11.1 ion channel cause long QT2 (LQT2) syndrome. This study reveals how a specific LQT2 mutation disrupts Kv11.1 channel function by affecting its phosphorylation by protein kinase C alpha (PKCα).

Area of Science:

  • Molecular biology
  • Cardiology
  • Ion channel physiology

Background:

  • Mutations in the Kv11.1 ion channel are linked to long QT2 (LQT2) syndrome, a condition causing cardiac arrhythmias and sudden death.
  • The precise molecular mechanisms underlying Kv11.1 malfunction in LQT2 remain largely unknown.
  • Disease-associated mutations can alter ion channel activity by affecting kinase consensus sites.

Purpose of the Study:

  • To investigate the molecular mechanism by which a LQT2-associated mutation affects Kv11.1 ion channel activity.
  • To determine the role of protein kinase C alpha (PKCα) and Ser890 phosphorylation in Kv11.1 channel function and LQT2 pathogenesis.

Main Methods:

  • Mass spectrometry to identify phosphorylation sites on Kv11.1.
  • Phospho-detection immunoassay and genetic manipulation to confirm PKCα phosphorylation of Ser890.
  • Electrophysiological studies and surface expression analysis to assess channel function.

Main Results:

  • Ser890 of the Kv11.1 ion channel is phosphorylated by PKCα.
  • PKCα-dependent phosphorylation of Ser890 influences Kv11.1 membrane density and recovery from inactivation.
  • A novel LQT2 mutation (R887H) inhibits PKCα-dependent phosphorylation of Ser890, reducing Kv11.1 surface expression and current density.

Conclusions:

  • The study provides a molecular link between a Kv11.1 mutation and LQT2 by demonstrating the role of PKCα-mediated phosphorylation of Ser890.
  • Perturbation of this phosphorylation site by mutations significantly impairs Kv11.1 channel function, contributing to LQT2 pathophysiology.

Related Concept Videos

Voltage-gated Ion Channels01:26

Voltage-gated Ion Channels

Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Non-gated Ion Channels01:24

Non-gated Ion Channels

Ion channels are specialized proteins on the plasma membrane that allow charged ions to pass down their electrochemical gradient. Their main function is to maintain the membrane potential which is critical for cell viability. These channels are either gated or non-gated and can transport more than a thousand ions within milliseconds for the cellular event to occur.
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism.
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Ion Channels01:19

Ion Channels

The movement of ions like sodium, potassium, and calcium into and out of the cell is essential to maintain the electrochemical gradient in living cells. The ion channels—a class of membrane transport proteins—help maintain this ionic gradient for the smooth functioning of physiological activities such as maintaining cell size and volume, conducting nerve impulses, and gas and nutrient exchange.
Ion channels are specialized integral membrane proteins on the plasma membrane that allow specific...